Baxdrostat, a once-daily pill, significantly lowered blood pressure in patients whose hypertension had resisted existing therapies. In the BaxHTN phase 3 trial, systolic blood pressure dropped by nearly 10 mmHg compared with placebo. About 40% of patients achieved healthy blood ...